---
title: "BUZZ-UniQure extends eye-watering rally ahead of planned $200 mln share offering"
description: "U.S.-listed shares of Dutch drugmaker UniQure surged approximately 248% to $47.50 following positive results from an early-to-mid-stage trial of its experimental gene therapy for Huntington's disease."
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/258922470.md"
published_at: "2025-09-25T15:50:14.000Z"
---

# BUZZ-UniQure extends eye-watering rally ahead of planned $200 mln share offering

> U.S.-listed shares of Dutch drugmaker UniQure surged approximately 248% to $47.50 following positive results from an early-to-mid-stage trial of its experimental gene therapy for Huntington's disease. The company plans a $200 million share offering and currently has about 54.9 million shares outstanding, with a market cap of around $2.6 billion. Short interest in UniQure shares has nearly tripled since the beginning of 2025, with about 8.3 million shares sold short as of September 25, representing approximately 16% of the public float.

U.S.-listed shares of Dutch drugmaker U

up ~248% at $47.50 after co said its experimental gene therapy significantly Huntington’s disease progression in an early-to-mid-stage trial

It also announced securing QURE has ~54.9 mln shares outstanding for about $2.6 bln current market cap through Weds

Short interest in QURE shares had nearly tripled from beginning of 2025 to about 9.7 mln shares in mid-Aug. As of Sept 25, about 8.3 mln shares were sold short, ~16% of the public float, per LSEG data (Lance Tupper is a Reuters market analyst. The views expressed are his own)

### Related Stocks

- [QURE.US - Uniqure](https://longbridge.com/en/quote/QURE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 美股盘中速递：uniQure 跌近 10%，成交量放大，市场波动性显著 | uniQure 跌 9.87%；阿里拉姆制药跌 6.23%，成交额达到 9.78 亿美元；Abivax SA 涨 4.72%，成交额达到 7.01 亿美元；再生元制药跌 2.98%，成交额达到 6.28 亿美元；艾伯维市值达到 3889 亿 | [Link](https://longbridge.com/en/news/272314286.md) |
| Uniqure 更新了其基因疗法管线和监管前景 | uniQure N.V. 更新了其基因治疗管线，强调其在该领域的领导地位，拥有强大的临床管线和充足的流动性。主要亮点包括用于亨廷顿舞蹈症的 AMT-130、即将发布的 AMT-260 和 AMT-191 数据，以及与 FDA 的接洽以申请潜 | [Link](https://longbridge.com/en/news/272411626.md) |
| Vanda 制药｜8-K：2025 财年 Q4 营收 57.22 百万美元不及预期 |  | [Link](https://longbridge.com/en/news/275657004.md) |
| Genes Tech 表示，方案股东已批准通过该方案的决议 | 基因科技集团控股有限公司：方案获得方案股东批准，涉及由 Watlow Electric Manufacturing Co.提出的将公司私有化的提案。预计在 2026 年 3 月 3 日将撤销在股票交易所 GEM 的上市 | [Link](https://longbridge.com/en/news/275917336.md) |
| BUZZ-Upstream Bio 股价上涨，因其实验性哮喘药物在中期研究中展现出良好前景 | Upstream Bio 的股票在盘前交易中上涨了 20%，达到 32.64 美元，此前其实验性哮喘药物 Verekitug 的中期研究结果积极。该药物在较低剂量下显示出 56% 的严重哮喘发作减少，而在较高剂量下减少了 39%，同时改善了 | [Link](https://longbridge.com/en/news/275596211.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.